<DOC>
	<DOCNO>NCT01715428</DOCNO>
	<brief_summary>Incretin-based therapy show significant effect beyond glucose metabolism . We aim present study evaluate effect liraglutide several cardio-metabolic risk marker .</brief_summary>
	<brief_title>Liraglutide Cardio-Metabolic Risk Markers</brief_title>
	<detailed_description>In detail , evaluate effect liraglutide carotid-intima medium thickness , oxidative stress , ghrelin , heat shock protein lipoprotein .</detailed_description>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>patient diagnosis type2 diabetes severe hepatic renal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>diabetes , cardiovascular risk</keyword>
</DOC>